News & Updates

Show Multimedia Only
GLP-1RA users face no elevated risk of pancreatic cancer

GLP-1RA users face no elevated risk of pancreatic cancer

16 Jan 2024 byJairia Dela Cruz

Among individuals with type 2 diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) does not contribute to increased pancreatic cancer risk, according to a study.

GLP-1RA users face no elevated risk of pancreatic cancer

16 Jan 2024
Repotrectinib shows high response rates, durable activity in ROS1 fusion–positive NSCLC

Repotrectinib shows high response rates, durable activity in ROS1 fusion–positive NSCLC

15 Jan 2024